Hammersmith score application identifies chronic myeloid leukemia patients with poor prognosis before treatment with second-generation tyrosine kinase inhibitors

Federica Sora', Simona Sica, M Breccia, F Stagno, A Gozzini, E Abruzzese, R Latagliata, Ar Rossi, R Porrini, P Vigneri, M Trawinska, E Montefusco, G Specchia, V Santini, G. Alimena

Risultato della ricerca: Contributo in rivistaArticolo in rivista

5 Citazioni (Scopus)

Abstract

In this study, we confirm the validity of the proposed Hammersmith score, which identifies three risk categories of patients and establish its strength on a large group of 128 chronic myeloid leukemia patients treated with second-generation tyrosine kinase inhibitors (TKIs) after being resistant to imatinib. Sixty-one patients were identified as good risk group, 27 patients as intermediate risk group, and 40 patients as poor risk group. The 1-year cumulative incidence of complete cytogenetic response was 73% in good risk patients, 40% in intermediate risk patients, and 22% in poor risk patients (P = 0.0001). Event-free survival at 3-year was 89% in good risk group, 70% in intermediate group, and 54% in poor risk group (P = 0.0001); the estimated 3-year progression-free survival was 95% in good risk category, 93% in intermediate risk category, and 87% in poor risk category (P = 0.05). Kaplan–Meier estimated that the 3-year overall survival was 100% in good risk category, 93% in intermediate risk category, and 82% in poor risk category (P = 0.04). In conclusion, some prognostic factors before starting second-generation TKIs might predict cytogenetic response and outcome. The so-called Hammersmith score was not yet validated in large series of patients: we demonstrated that this score is able to discriminate patients at high risk of failure and consequent progression before treatment with second-generation TKIs.
Lingua originaleEnglish
pagine (da-a)523-525
Numero di pagine3
RivistaAmerican Journal of Hematology
Volume86
DOI
Stato di pubblicazionePubblicato - 2011

Keywords

  • Female
  • Humans
  • Italy
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive
  • Male
  • Middle Aged
  • Predictive Value of Tests
  • Prognosis
  • Protein Kinase Inhibitors
  • Risk Assessment
  • Survival Analysis

Fingerprint Entra nei temi di ricerca di 'Hammersmith score application identifies chronic myeloid leukemia patients with poor prognosis before treatment with second-generation tyrosine kinase inhibitors'. Insieme formano una fingerprint unica.

Cita questo